MeiraGTx Holdings (MGTX) Depreciation & Amortization (CF) (2020 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Depreciation & Amortization (CF) came in at $3.1 million in Q4 2025, up 1.43% YoY from $3.1 million in Q4 2024, and down 1.27% on a QoQ basis from $3.2 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $3.1 million in Q4 2025.
- Quarterly Depreciation & Amortization (CF) rose 1.43% year-over-year to $3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $12.5 million (down 2.21% YoY) and the FY2025 annual result came in at $12.5 million, down 2.23% from the prior year.
- Depreciation & Amortization (CF) eased to $3.1 million in Q4 2025, from $3.2 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.9 million in Q4 2023 to a low of $1.8 million in Q1 2021.
- A 5-year average of $2.8 million and a median of $3.1 million in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2021 — Depreciation & Amortization (CF) surged 115.71% — and 2024, when it dropped 21.5%.
- Tracing MGTX's Depreciation & Amortization (CF) over 5 years: stood at $2.1 million in 2021, then increased by 20.85% to $2.5 million in 2022, then jumped by 56.98% to $3.9 million in 2023, then dropped by 21.5% to $3.1 million in 2024, then rose by 1.43% to $3.1 million in 2025.
- The last three Depreciation & Amortization (CF) figures came in at $3.1 million (Q4 2025), $3.2 million (Q3 2025), and $3.2 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | 2.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.83 Mn |
| Dec 31, 2025 | 3.12 Mn |
| Sep 30, 2025 | 3.16 Mn |
| Jun 30, 2025 | 3.19 Mn |
| Mar 31, 2025 | 3.08 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Sep 30, 2024 | 3.26 Mn |
| Jun 30, 2024 | 3.22 Mn |
| Mar 31, 2024 | 3.28 Mn |
| Dec 31, 2023 | 3.91 Mn |
| Sep 30, 2023 | 3.48 Mn |
| Jun 30, 2023 | 3.25 Mn |
| Mar 31, 2023 | 3.09 Mn |
| Dec 31, 2022 | 2.49 Mn |
| Sep 30, 2022 | 2.03 Mn |
| Jun 30, 2022 | 2.09 Mn |
| Mar 31, 2022 | 2.12 Mn |
| Dec 31, 2021 | 2.06 Mn |
| Sep 30, 2021 | 2.04 Mn |
| Jun 30, 2021 | 2.02 Mn |